ストックスクリーナーアプリを入手
2.445
2.59%
-0.065
前日終値:
$2.51
開ける：
$2.51
24時間の取引高:
861.44K
Relative Volume:
0.22
時価総額：
$284.99M
収益：
$6.65M
当期純損益:
$-136.32M
株価収益率:
-2.1303
EPS:
-1.1477
ネットキャッシュフロー:
$-112.04M
1週間 パフォーマンス:
+1.45%
1か月 パフォーマンス:
-9.44%
6か月 パフォーマンス:
+105.46%
1年 パフォーマンス:
+122.27%
1日の値動き範囲:
$2.39
$2.555
1週間の範囲:
$2.25
$2.555
52週間の値動き範囲:
$0.91
$3.23
Fate Therapeutics Inc Stock (FATE) Company Profile
名前
Fate Therapeutics Inc
セクター
電話
858.875.1803
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
2.445 | 283.24M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-05-19 | 再開されました | Jefferies | Buy |
| 2025-10-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-11-18 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-06-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-01-06 | ダウングレード | Cowen | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | ダウングレード | Stifel | Buy → Hold |
| 2023-01-06 | ダウングレード | Truist | Buy → Hold |
| 2023-01-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 開始されました | Goldman | Sell |
| 2022-11-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-08-18 | 再開されました | Wells Fargo | Overweight |
| 2022-07-28 | 開始されました | Needham | Hold |
| 2022-07-11 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 開始されました | Robert W. Baird | Neutral |
| 2022-02-11 | 再開されました | BMO Capital Markets | Market Perform |
| 2021-12-15 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-11-09 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-07 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Jefferies | Buy |
| 2021-02-26 | 開始されました | BofA Securities | Buy |
| 2021-02-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-02-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-27 | 再開されました | H.C. Wainwright | Neutral |
| 2020-05-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-09 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 繰り返されました | Mizuho | Buy |
| 2019-12-09 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-06 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-06-07 | 開始されました | ROTH Capital | Neutral |
| 2019-05-31 | 開始されました | Guggenheim | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2019-03-28 | 開始されました | SVB Leerink | Outperform |
| 2019-01-03 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 開始されました | Jefferies | Buy |
| 2018-08-01 | 開始されました | Citigroup | Buy |
| 2018-03-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
すべてを表示
Fate Therapeutics Inc (FATE) 最新ニュース
Cash flow from operating activities of Fate Therapeutics, Inc. – HAM:F6T - TradingView
FATE|Fate Therapeutics Inc|Price:2.420|Chg%:+0.010 - TradingKey
Fate Therapeutics Inc (FATE) Cash Flow - TradingKey
Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fate Therapeutics, Inc. Revenue Breakdown – NASDAQ:FATE - TradingView
Fate Therapeutics Inc (FATE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
FATE News | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
BlackRock, Inc. Reduces Stake in Fate Therapeutics Inc - GuruFocus
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits
FDA approves clinical testing of CAR T-cell therapy for AAV, other conditions - ANCA Vasculitis News
Fate Therapeutics Inc (FATE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $3.11 - Moomoo
Fate Therapeutics’ FT-839 gains IND clearance - BioWorld News
H.C. Wainwright reiterates Fate Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Fate Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Can Fate Therapeutics (NASDAQ:FATE) Boost Healthcare Stocks? - Kalkine Media
FT819 shows first clinical activity in systemic sclerosis - CRISPR Medicine News
Fate Therapeutics Inc (FATE) Institutional Confidence - TradingKey
Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 - Moomoo
Sector Update: Healthcare - Moomoo
Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 - marketscreener.com
Fate Therapeutics receives FDA clearance for FT839 IND - grafa.com
Fate Therapeutics gains after IND clearance (FATE:NASDAQ) - Seeking Alpha
Fate Therapeutics Receives FDA Clearance Of Investigational New Drug Application For FT839 Product Candidate - marketscreener.com
Fate Therapeutics Announces FDA Clearance of IND for FT839 Dual-CAR T Cell Therapy in Autoimmune Disease - Quiver Quantitative
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate - GlobeNewswire
Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade) - Seeking Alpha
Fate Therapeutics looks to its pipeline as investors weigh long-term prospects - ad-hoc-news.de
Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54 - simplywall.st
Fate Therapeutics Presents Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis At ISSCR 2026 Annual Meeting - marketscreener.com
Fate Therapeutics to present FT819 data at stem cell meeting - Investing.com
Fate Therapeutics to present FT819 data at stem cell meeting By Investing.com - Investing.com Nigeria
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting - The Manila Times
Fate Therapeutics Announces Preliminary FT819 Data in Systemic Sclerosis for ISSCR 2026 Presentation - Quiver Quantitative
Fate Therapeutics to show early FT819 data in systemic sclerosis - Stock Titan
Fate Therapeutics (FATE) Slides to $2.92 as Support Levels Come Into FocusVolume Gap - dars.gov.et
Fate Therapeutics focuses on cell-based immunotherapy and long-term growth prospects - Ad-hoc-news.de
Fate Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline AdvancesEstimate Accuracy - dars.gov.et
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - The Manila Times
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Fate Therapeutics(FATE) Stock Options Chain | Quotes & News - Moomoo
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000 Value Benchmark - marketscreener.com
Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade
Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History - Benzinga
F6T Forecast — Price Target — Prediction for 2027 - TradingView
Fate Therapeutics sets out next steps, biotech stock in focus after cash preservation move - Ad-hoc-news.de
Fate Therapeutics Inc (FATE) 財務データ
収益
当期純利益
現金流量
EPS
Fate Therapeutics Inc (FATE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
May 20 '26 |
Sale |
1.88 |
28,946 |
54,482 |
635,762 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):